Why Achillion Pharmaceuticals, Receptos, and Galena Biopharma Are Today's 3 Best Stocks

The S&P 500's winning streak comes to a subtle end as three biotech stocks roar higher.

Jun 10, 2014 at 5:15PM

The broad-based S&P 500 (SNPINDEX:^GSPC) can't go up every day, can it? No. Unfortunately, no index is going to go straight up, but it's certainly felt that way for a while with the iconic index hitting a fresh all-time closing high in 10 of the past 13 sessions.


Most of the economic data released on this light day was generally positive and would have been conducive to push the index to another closing high. According to an early morning release from the U.S. Commerce Department, wholesale inventories rose 1.1% in April, matching the 1.1% gain in March. This increase was a bit more than economists had predicted and signals that businesses expect robust growth in the coming months (thus the increase in inventories).

However, even optimists need to step back and take profits now and then, and today appeared to be the perfect opportunity for them to do just that. By day's end the S&P 500 had dipped by a very subtle 0.48 points (-0.02%) to close at 1,950.79. Despite the dip, the biotech sector was a source of huge gains for investors looking for rays of sunshine on a moderately cloudy day.

Leading all individual companies to the upside today was Achillion Pharmaceuticals (NASDAQ:ACHN), which skyrocketed 83.3% (following yesterday's gain of 47.6%) after announcing a double-dose of good news. First, the Food and Drug Administration finally released its clinical hold on Achillion's lead drug sovaprevir, a potential treatment for hepatitis C, after elevated ALT liver enzymes were discovered in patients last year following a phase 1 study. According to Achillion's press release, the company will be allowed to continue once-daily dosing at 200 milligrams, a dose that was consistent with good tolerability in previous studies.

Also, Achillion noted that it would begin dosing genotype-1 HCV patients in a proof-of-concept phase 1 study utilizing ACH-3422, a uridine-analog nucleotide polymerase inhibitor. The seven-day treatment should yield reportable results for Achillion by the fall.

While this is clearly great news for existing shareholders, and it certainly lends credence to Achillion possibly being a buyout target with its lead drug now off clinical hold, I still can't help but be concerned about the fact that the company has yet to get any of its clinical products past midstage studies. Until that happens I'd suggest keeping your nose clean of Achillion.

Source: National Cancer Institute, Wikimedia Commons.

Following behind Achillion was clinical-stage biopharmaceutical company Receptos (NASDAQ:RCPT), which surged 36.8% after reporting positive phase 2 results for RPC1063, a treatment for relapsing multiple sclerosis. Based on the study data from its RADIANCE trial released after the closing bell last night, RPC1063 in both its 0.5 mg and 1 mg oral dose led to a statistically significant 86% reduction in gadolinium-enhancing brain lesions. Receptos has also been enrolling since December under a special protocol assessment that will compare RPC1063 to Biogen Idec's Avonex in a head-to-head phase 3 study involving 1,200 patients.

This is also good news for investors, but keep in mind that with a valuation near $900 million and only two investigational therapies in its entire pipeline, Receptos' room for error is shrinking with each tick higher in its share price. As such, I'd rather watch this company safely from the sidelines until after its phase 3 data is released.

Lastly, cancer immunotherapy drug developer Galena Biopharma (NASDAQ:GALE) saw its shares rocket higher by 16.8% despite no company-specific news today. Galena shares, however, have been practically unstoppable since releasing phase 1 study data last week. In that study, involving GALE-301, Galena noted that out of 30 enrolled patients with ovarian or endometrial cancer, seven out of 14 in the control arm had their cancer reoccur. Out of the 16 GALE-301 intent-to-treat patients, four had their cancer reoccur after completing the vaccine series, two had their cancer reoccur prior to completion, and one patient withdrew.

Possibly the biggest factor in today's continuation move higher for Galena is its nearly 23% short interest. A rapid increase in Galena's share price forces short-sellers to either endure the pain or cover their short shares, possibly sending Galena even higher.

I personally am keeping a close eye on Galena as its HER2-negative breast cancer adjuvant therapy NeuVax has the potential to put the company on the map, but until I see its phase 3 results I'm perfect satisfied sticking to the sidelines.

These 3 bitoech stocks may have soared today, but they'll likely be no match for this top stock over the long run
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers